| Objective: Adjuvant multi-disciplinary therapy after breast cancer surgery is becoming a standard approach. Nowadays chemotherapy and radiotherapy are widely delivered in sequential approaches. But delayed radiotherapy or chemotherapy could lead local-regional control or disease-free survival rate decrease. Concurrent adjuvant chemoradiotherapy for operable breast cancer start early both therapies. But its feasibility is controversial because of a possible increase of acute toxicities. With the development of evidence-based medicine, more and more randomized clinical trial data demonstrate that concurrent adjuvant chemoradiotherapy is feasibility when proper chemotherapy schedules are practiced, with a substantially higher disease-free survival and local control rate. In this study, we evaluated the feasibility of concurrent adjuvant chemoradiotherapy for breast cancer by observing acute toxicities.Methods : From April 2002 to January 2007, 48 stage I -III_A breast cancer patients, treated with conserving surgery or modified radical mastectomy were treated at the PLA General Hospital. Ipsilateral breast or chest wall and regional nodes were irradiated with a dose of 45-50Gy/23-25F (5 fractions per week). The radiotherapy was combined with variety chemotherapy regimens. Acute toxicities were recorded.Results : In all 48 patients, Grade III-IV neutropathy and toxicities of skin, gastro-intestin and liver occurred in 10, 1, 1 and 1 patients, respectively; without grade III-IV esophageal and peripheral neural toxicities. Treatments were brokenoff in 4 patients, and radiation therapy was delayed in 2 patients.Conclusions: Breast cancer patients can tolerate concurrent adjuvant chemoradiotherapy, indicating studies for its indications and clinical outcome are warranted.
|
PDF Full Text Request